Self-adaptive Bat Algorithm With Genetic Operations

Swarm intelligence in a bat algorithm(BA)provides social learning.Genetic operations for reproducing individuals in a genetic algorithm(GA)offer global search ability in solving complex optimization problems.Their integration provides an opportunity for improved search performance.However,existing studies adopt only one genetic operation of GA,or design hybrid algorithms that divide the overall population into multiple subpopulations that evolve in parallel with limited interactions only.Differing from them,this work proposes an improved self-adaptive bat algorithm with genetic operations(SBAGO)where GA and BA are combined in a highly integrated way.Specifically,SBAGO performs their genetic operations of GA on previous search information of BA solutions to produce new exemplars that are of high-diversity and high-quality.Guided by these exemplars,SBAGO improves both BA’s efficiency and global search capability.We evaluate this approach by using 29 widely-adopted problems from four test suites.SBAGO is also evaluated by a real-life optimization problem in mobile edge computing systems.Experimental results show that SBAGO outperforms its widely-used and recently proposed peers in terms of effectiveness,search accuracy,local optima avoidance,and robustness.

Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development

Objectives:The Kirsten rat sarcoma virus(KRAS)G12D oncogenic mutation poses a significant challenge in treating solid tumors due to the lack of specific and effective therapeutic interventions.This study aims to explore innovative approaches in T cell receptor(TCR)engineering and characterization to target the KRAS G12D7-16 mutation,providing potential strategies for overcoming this therapeutic challenge.Methods:In this innovative study,we engineered and characterized two T cell receptors(TCRs),KDA11-01 and KDA11-02 with high affinity for the KRAS G12D7-16 mutation.These TCRs were isolated from tumor-infiltrating lymphocytes(TILs)derived from tumor tissues of patients with the KRAS G12D mutation.We assessed their specificity and anti-tumor activity in vitro using various cancer cell lines.Results:KDA11-01 and KDA11-02 demonstrated exceptional specificity for the HLA-A*11:01-restricted KRAS G12D7-16 epitope,significantly inducing IFN-γrelease and eliminating tumor cells without cross-reactivity or alloreactivity.Conclusions:The successful development of KDA11-01 and KDA11-02 introduces a novel and precise TCR-based therapeutic strategy against KRAS G12D mutation,showing potential for significant advancements in cancer immunotherapy.